JAC Advance Access originally published online on December 8, 2004
Journal of Antimicrobial Chemotherapy 2005 55(1):10-21; doi:10.1093/jac/dkh519
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
JAC vol.55 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Review |
Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
The Clinical Pharmacology Research Center and Department of Adult and Pediatric Medicine, Bassett Healthcare, Cooperstown, NY, USA
* Correspondence address. Clinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326, USA. Tel: +1-607-547-3399; Fax: +1-607-547-6914; Email: guy.amsden{at}bassett.org
Background: It has been recognized for more than 20 years that the macrolides have immunomodulatory effects that are beneficial for those suffering from chronic pulmonary inflammatory syndromes, such as diffuse panbronchiolitis, cystic fibrosis, asthma and bronchiectasis. The macrolides have consistently been associated with decreased length of stay and mortality when used alone or in combination with ß-lactam antibiotics. This effect can be demonstrated against combinations consisting of ß-lactams and other antibiotics active against ‘atypical chest pathogens’ when treating community-acquired pneumonia (CAP) in hospitalized patients. As such, it appears that the macrolides' effects in CAP patients are more than just antibacterial in nature.
Aims of this review: This review aims: to give the reader information on the background areas described, as well as related areas; to review the CAP benefits with macrolides and how they may be related to the immunomodulatory properties they demonstrate, albeit in a shorter period of time than previously demonstrated with chronic pulmonary disorders; to use ex vivo data to support these extrapolations.
Literature search: A literature search using Medline was conducted from 1966 onwards, searching for articles with relevant key words such as macrolide, diffuse panbronchiolitis, community-acquired pneumonia, biofilm, immunomodulation, cystic fibrosis, erythromycin, clarithromycin, roxithromycin and azithromycin, bronchiectasis and asthma. When appropriate, additional references were found from the bibliographies of identified papers of interest. Any relevant scientific conference proceedings or medical texts were checked when necessary.
Conclusions: (1) Research into macrolide immunomodulation for chronic pulmonary disorders demonstrates consistent positive effects, although of types other than seen with diffuse panbronchiolitis. These effects, together with their inhibitory activity on biofilms, have the potential to make them a useful option. (2) The benefits for CAP are consistent, and higher when a macrolide is given with another atypical agent than if the other atypical agent is given alone, suggesting a non-antibacterial benefit. (3) Recent research of the immunomodulatory properties of azithromycin imply that azithromycin may have a previously unknown short-term biphasic effect on inflammation modulation: enhancement of host defence mechanisms shortly after initial administration followed by curtailment of local infection/inflammation in the following period. (4) Additional in vivo research is needed prior to developing any firm conclusions.
Keywords: azithromycin , clarithromycin , erythromycin , pneumonia , diffuse panbronchiolitis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. I. Restrepo, E. M. Mortensen, G. W. Waterer, R. G. Wunderink, J. J. Coalson, and A. Anzueto Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Eur. Respir. J., January 1, 2009; 33(1): 153 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Diaz, E. M. Mortensen, A. Anzueto, and M. I. Restrepo Review: Novel targets in the management of pneumonia Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 387 - 400. [Abstract] [PDF]
|
|
|
|
 |
|
 G. A. Tramper-Stranders, C. K. van der Ent, S. A. M. Gerritsen, A. Fleer, J. L. L. Kimpen, and T. F. W. Wolfs Macrolide-resistant Staphylococcus aureus colonization in cystic fibrosis patients: is there transmission to household contacts? J. Antimicrob. Chemother., September 1, 2007; 60(3): 665 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Hawkyard and R. J. Koerner The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J. Antimicrob. Chemother., March 1, 2007; 59(3): 347 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Sharp, D. Denman, S. Puumala, and D. A. Leopold Treatment of Acute and Chronic Rhinosinusitis in the United States, 1999-2002 Arch Otolaryngol Head Neck Surg, March 1, 2007; 133(3): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Metersky, A. Ma, P. M. Houck, and D. W. Bratzler Antibiotics for Bacteremic Pneumonia: Improved Outcomes With Macrolides but Not Fluoroquinolones Chest, February 1, 2007; 131(2): 466 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Anderson, H. C. Steel, R. Cockeran, A. M. Smith, A. von Gottberg, L. de Gouveia, A. Brink, K. P. Klugman, T. J. Mitchell, and C. Feldman Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae J. Antimicrob. Chemother., February 1, 2007; 59(2): 224 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nisar, R. Guleria, S. Kumar, T. Chand Chawla, and N. Ranjan Biswas Mycoplasma pneumoniae and its role in asthma Postgrad. Med. J., February 1, 2007; 83(976): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-{kappa}B activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L343 - L352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Clement, A Tamalet, E Leroux, S Ravilly, B Fauroux, and J-P Jais Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial Thorax, October 1, 2006; 61(10): 895 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lotter, K. Hocherl, M. Bucher, and F. Kees In vivo efficacy of telithromycin on cytokine and nitric oxide formation in lipopolysaccharide-induced acute systemic inflammation in mice J. Antimicrob. Chemother., September 1, 2006; 58(3): 615 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Giamarellos-Bourboulis, V. Tziortzioti, P. Koutoukas, F. Baziaka, M. Raftogiannis, A. Antonopoulou, T. Adamis, L. Sabracos, and H. Giamarellou Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae J. Antimicrob. Chemother., May 1, 2006; 57(5): 937 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Raderer, B Streubel, S Wohrer, M Hafner, and A Chott Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas Gut, May 1, 2006; 55(5): 616 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. West, E. S. West, W. Alemayehu, M. Melese, B. Munoz, A. Imeru, A. Worku, C. Gaydos, C. L. Meinert, and T. Quinn Single-Dose Azithromycin Prevents Trichiasis Recurrence Following Surgery: Randomized Trial in Ethiopia. Arch Ophthalmol, March 1, 2006; 124(3): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shinkai, G. H. Foster, and B. K. Rubin Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L75 - L85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Rios, M. Fonseca-Aten, A. Mejias, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr., O. Ramilo, and R. D. Hardy Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3970 - 3973. [Abstract] [Full Text] [PDF]
|
|